Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
I would treat this as an urgent patient-safety and governance event, not as an earnings-management problem. A suspected fatal or life-threatening adverse effect affecting potentially hundreds of patients is sufficient to trigger immediate escalation, investigation, and regulator contact.Read the full answer
I would treat this as a credible, urgent safety signal, not as a finding that can wait six months for a completed regulatory submission. The estimate—liver failure in roughly 1 in 8,000 patients over five years—needs validation, but the outcome is severe and the current warning omits it.Read the full answer